The buyout will give Sanofi rights over Tzield (teplizumab-mzwv), Provention’s diabetes delay drug, which is the first-ever disease-modifying treatment to delay disease progression.
Tag Archive for: TZIELD
The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease progression.
That means a 14-day regimen of the drug would translate to a price of $193,900, the company said on a conference call.